Patent US3966906A successfully refreshed from Google Patents.
← Back to Patent Explorer
US3966906A Expired / Lapsed US ⏱️ 0.0 years remaining

Disaggregated gamma globulin and process for preparing it

Assignee: Siemens Healthcare Diagnostics GmbH Germany
•
Filing: 1974-04-08
•
Granted: 1976-06-29
•
Expires: 1994-04-08
📄 Original PDF 🌐 Google Patents 🔄 Sync Now

Abstract

Abstract A disaggregated gamma globulin, suitable for intravenous injection for purposes of therapy and prophylaxis by means of antibodies, prepared by treating a crude gamma globulin fraction of human serum with pepsin, removing lower degradation products by filtration, and then filtering under sterile conditions.

Inventors

  • 👤 Hermann E. Schultze
  • 👤 Hans Gerhard Schwick

Bibliographic Details

Application Number —
Jurisdiction US
Data Source google_patents
Last Synchronized 2026-10-26 08:22
CPC Classifications
C; C07; C07K; C07K16/00; C07K16/06; C07K16/065; A; A61; A61K; A61K38/00; Y; Y10; Y10S; Y10S530/00; Y10S530/827; Y10S530/829; Y10S530/83

Claims Analysis

Total Claims: 10
Claim 1
Independent Claim 180 words
The process for preparing a human gamma globulin disaggregated into sub-units by enzymatic action and having no significant effect on the complement system, which process comprises (1) treating a crude antibody-containing gamma globulin fraction of human serum, obtained by precipitating blood serum with ammonium sulfate or alcohol, at a pH between 3.5 and 5 and at a temperature from 25°C. to 45°C. with from 50,000 MTU to 100,000 MTU of pepsin per 100 grams of protein to be degraded, while continually controlling the anticomplement activity, for a period ranging from 12 to 48 hours, until the anti-complement activity, measured by combining a 1 ml sample of the disaggregated gamma globulin with 1 ml of a solution containing 100 units of guinea pig complement in the presence of a buffer solution and heating for 1 hour at 30°C., is such that more than 20 units of the complement in the original complement solution must not be inactivated; (2) removing low molecular weight decomposition products from the disaggregated gamma globulin by filtration; and (3) filtering the disaggregated gamma globulin under sterile conditions.
Claim 2
Dependent Claim 180 words
The process for preparing a human gamma globulin disaggregated into sub-units by enzymatic action and having no significant effect on the complement system, which process comprises (1) treating a crude antibody-containing gamma globulin fraction of human serum, obtained by precipitating blood serum with ammonium sulfate or alcohol, at a pH between 3.5 and 5 and at a temperature from 25°C. to 45°C. with from 50,000 MTU to 100,000 MTU of pepsin per 100 grams of protein to be degraded, while continually controlling the anticomplement activity, for a period ranging from 12 to 48 hours, until the anti-complement activity, measured by combining a 1 ml sample of the disaggregated gamma globulin with 1 ml of a solution containing 100 units of guinea pig complement in the presence of a buffer solution and heating for 1 hour at 30°C., is such that more than 20 units of the complement in the original complement solution must not be inactivated; (2) removing low molecular weight decomposition products from the disaggregated gamma globulin by filtration; and (3) filtering the disaggregated gamma globulin under sterile conditions.
Claim 3
Dependent Claim 13 words
The process of claim 1 wherein the sterile-filtered disaggregated gamma globulin is lyophilized.
Claim 4
Dependent Claim 35 words
A process for therapy and prophylaxis utilizing antibodies which comprises intravenously injecting an effective amount of a composition having as its essential active ingredient the disaggregated gamma globulin prepared by the process of claim 1.
Claim 5
Dependent Claim 39 words
The process of claim 1 wherein said crude gamma globulin fraction is treated at a pH of 4.0 and a temperature of 40°C. with 90,000 MTU of pepsin per 100 grams of protein to be degraded for 24 hours.
Claim 6
Dependent Claim 13 words
The process of claim 4 wherein the sterile-filtered disaggregated gamma globulin is lyophilized.
Claim 7
Dependent Claim 35 words
A process for therapy and prophylaxis utilizing antibodies which comprises intravenously injecting an effective amount of a composition having as its essential active ingredient the disaggregated gamma globulin prepared by the process of claim 4.
Claim 8
Dependent Claim 24 words
A preparation of human gamma globulin disaggregated into sub-units by enzymatic action and suitable for intravenous injection, prepared by the process of claim 1.
Claim 9
Dependent Claim 12 words
The preparation of claim 7 in a sterile, pyrogen-free, physiological salt solution.
Claim 10
Dependent Claim 8 words
The preparation of claim 7 in lyophilized form.

References Cited (Backward Citations)

US2065196A Cited

USPTO Annuity & Maintenance Windows

Annuity Stage Window Opens Payment Deadline Surcharge Period Until Estimated Fee Status
3.5 Years (Year 4) 1979-06-29 1979-12-29 1980-06-29 $2000.00 Window Closed / Lapsed
7.5 Years (Year 8) 1983-06-29 1983-12-29 1984-06-29 $3760.00 Window Closed / Lapsed
11.5 Years (Year 12) 1987-06-29 1987-12-29 1988-06-29 $7700.00 Window Closed / Lapsed

Assigned Categories & Tags

No categories assigned to this patent yet.

Assign Category Tag